After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration.
The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).
“Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is proud to deliver Cosela to patients and their families as the first and only therapy to help protect against chemotherapy-induced myelosuppression.”
Commerce Chenango in Norwich will host their annual Economic Outlook Briefing Feb. 25 in partnership with NBT Bank and supporting sponsor Preferred Mutual.
NBT senior vice president and chief investment officer Kenneth J. Entenmann, CFA, will serve as keynote speaker. Entenmann has more than 33 years of investment experience and for the past seven years has provided attendees with a great overview of the economy, both local, statewide and global. This year’s presentation will help to define some of the economic impacts due to COVID-19.
“While this year’s Economic Outlook event will look a little different, we are pleased that Ken will once again join us virtually to share his ‘outlook’ on our economy. This discussion is critical to the recovery efforts here in Chenango County, and in the Southern Tier,” said Commerce Chenango president and CEO Kerri Green. “While no one knows how 2021 will unfold, it’s evident that we need to have serious discussions now about recov
Indianapolis-based Apria Inc. (Nasdaq: APR) has begun listing on the Nasdaq Global Select Market after an Initial Public Offering this week. The home healthcare equipment provider is looking to raise
Decibel Therapeutics Announces Pricing of Initial Public Offering
BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Decibel. In addition, Decibel has granted the underwriters a 30-day option to purchase up to an additional 1,059,300 shares of common stock at the public offering price, less underwriting discounts and commissions.
The dating app's IPO made its co-founder, Whitney Wolfe Herd, the youngest woman CEO to take a large company public and one of the few self-made female billionaires.